Abbott Laboratories $ABT Stock Acquired by Moody National Bank Trust Division

Moody National Bank Trust Division grew its stake in shares of Abbott Laboratories (NYSE:ABT) by 35.3% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 20,659 shares of the healthcare product maker’s stock after purchasing an additional 5,387 shares during the quarter. Moody National Bank Trust Division’s holdings in Abbott Laboratories were worth $2,042,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Iowa State Bank grew its position in shares of Abbott Laboratories by 10.8% during the third quarter. Iowa State Bank now owns 18,491 shares of the healthcare product maker’s stock valued at $1,827,000 after purchasing an additional 1,809 shares in the last quarter. Legacy Private Trust Co. lifted its position in shares of Abbott Laboratories by 3.0% in the third quarter. Legacy Private Trust Co. now owns 26,104 shares of the healthcare product maker’s stock worth $2,580,000 after buying an additional 749 shares in the last quarter. Rosenberg Matthew Hamilton boosted its stake in Abbott Laboratories by 42.9% during the third quarter. Rosenberg Matthew Hamilton now owns 3,683 shares of the healthcare product maker’s stock valued at $364,000 after buying an additional 1,106 shares during the last quarter. Baker Tilly Wealth Management LLC purchased a new position in Abbott Laboratories during the 3rd quarter valued at approximately $323,000. Finally, Argent Capital Management LLC bought a new stake in Abbott Laboratories in the 3rd quarter worth approximately $211,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Down 2.0%

Shares of Abbott Laboratories stock traded down $1.96 on Tuesday, reaching $98.14. The company had a trading volume of 10,575,706 shares, compared to its average volume of 11,348,987. The firm has a market cap of $169.82 billion, a price-to-earnings ratio of 31.76, a P/E/G ratio of 1.81 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The firm’s 50-day moving average price is $106.89 and its two-hundred day moving average price is $98.52. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $135.13.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.Abbott Laboratories’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, research analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ABT. Bank of America decreased their price objective on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Citigroup boosted their price target on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. JPMorgan Chase & Co. upped their price target on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Piper Sandler reiterated an “overweight” rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Finally, UBS Group reduced their target price on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $119.80.

Abbott Laboratories Profile

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.